Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
- 30 June 2005
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 48 (3) , 349-355
- https://doi.org/10.1016/j.lungcan.2004.11.020
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Role of Adjuvant Chemotherapy in Patients With Resected Non–Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled TrialsJournal of Clinical Oncology, 2004
- Conditional Survival of Patients With the Four Major Histologic Subgroups of Lung Cancer in DenmarkJournal of Clinical Oncology, 2003
- Neoadjuvant and adjuvant therapy of non-small cell lung cancerSurgical Oncology, 2002
- Non-small Cell Lung CancerChest, 1999
- The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interactionFEBS Letters, 1997
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patientsEuropean Journal Of Cancer, 1997
- Cell‐Surface Acceleration of Urokinase‐Catalyzed Receptor CleavageEuropean Journal of Biochemistry, 1997
- Domain Interplay in the Urokinase ReceptorJournal of Biological Chemistry, 1996
- A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumorsInternational Journal of Cancer, 1994